Identification of antibodies against difficult targets

Supported by:

15 September 2015

Supported by:

15 September 2015

Identification of antibodies against difficult targetsAbout this webinar

Learn about the identification of antibodies against challenging targets using high throughput multiplex-screening approaches by watching the webinar by Markus Waldhuber, Ph.D. at MorphoSys AG.

This webinar was provided by Intellicyt

IntelliCyt Corporation is the market leader in suspension-cell analysis platforms for immunology and immuno-oncology profiling, antibody discovery, and screening of immune targets in drug discovery and life science research.

IntelliCyt’s iQue Screener can rapidly and cost effectively profile physiologically-relevant model systems for phenotypic endpoints using multiplexed cell and/or bead-based assays.

Our easy-to-use instruments, software, and reagent kits are optimized to work together and designed to conserve precious samples, use less reagent, and minimize time-to-answer. Our high-content solution offers fast and rich per-cell information that delivers the deep insight that complex biology demands.

The top 10 pharmaceutical companies and premier biotechnology and academic institutes, including leaders in immuno-oncology, have made the iQue Screener platform an integral part of their daily research.

View more content from Intellicyt

Send this to a friend